Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.

Saudi medical journal - 1 Dec 2023

AlGhamdi Hamdan S, AlHabobi Ali A, AlQahtani Rakan S, Ghomraoui Firas A, AlThiab Khalefa M, AlOun Abdulrahman A, AlAlwan Abduljaleel M, Abdelmahmoud Mutaz B, AlTraif Ibrahim H, Aljumah Abdulrahman A

Abstract excerpt

OBJECTIVES: To assess the effectiveness of generic sofosbuvir (SOF) and branded daclatasvir (DCV) for the treatment of chronic hepatitis C virus (HCV)infected patients. METHODS: This retrospective study, performed in a single center in Saudi Arabia between August 2017 and July 2022, we enrolled 140 consecutive patients with HCV who received generic SOF and branded DCV. The primary outcome was sustained virologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Ribavirin

Share to Saudi Arabia

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 38016752
DOI: 10.15537/smj.2023.44.12.20230481
PMCID: PMC10712790

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.PMID 38016752Read ↗

Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.Semantic proximity Read ↗

High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.Semantic proximity Read ↗

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.Semantic proximity Read ↗

Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia.Semantic proximity Read ↗

Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.Semantic proximity Read ↗

Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.Semantic proximity Read ↗

Direct-acting antiviral agents in the treatment of chronic Hepatitis C – Real-life experience from clinical practices in PakistanSemantic proximity Read ↗

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.Semantic proximity Read ↗

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.Semantic proximity Read ↗

Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.Semantic proximity Read ↗

[A real-world study of sofosbuvir-based drug treatment for hepatitis C virus genotype 6 infection in Hainan region of China].Semantic proximity Read ↗

Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.